Trump's Small Financial Stake in Hydroxychloroquine Maker

Topline: President Trump—increasingly a booster of hydroxychloroquine as a potential treatment for coronavirus—has a “small personal financial interest” in Sanofi, a French drugmaker that produces a brand-name version of the drug—though it’s a tiny investment for the billionaire.

Sanofi produces Plaquenil, the brand-name form of hydroxychloroquine, the New York Times reported; the drug is typically used to treat rheumatoid arthritis, lupus and malaria.
Trump’s three family trusts have investments in a Dodge & Cox mutual fund, with Sanofi as the largest holding, according to the Times.
Forbes estimates the value...

As President Donald Trump has persistently discussed the malaria drug hydroxychloroquine, critics have wondered about his motivation, given the drug’s far-from-certain performance on the global stage as a treatment for coronavirus, and the Food and Drug Administration’s refusal so far to approve it as a treatment for COVID-19.

The New York Times says Trump has a “small personal stake” in Sanofi, the French drug manufacturer that produces the drug.

The report doesn’t say how small, but it notes that his three family trusts have investments in a Dodge & Cox...